Fred Saad, Martin Bögemann, Kazuhiro Suzuki & Neal Shore Click here to read more.
Author Archive for: CURC
This author has not written his bio yet.
But we are proud to say that CURC contributed 214 entries already.
Entries by CURC
Daniel E. Spratt, Neal Shore, Oliver Sartor, Dana Rathkopf & Kara Olivier Click here to read more.
Dr. Shore, an expert in urologic oncology, discusses hormonal therapy in prostate cancer. He leads an educational discussion and course on prostate cancer for learning clinicians. The activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other professionals involved in the management of patients with prostate cancer. For clinicians to […]
Key Issues For The Advanced Bladder Cancer Clinic: Incorporating Immunotherapy Into Your Community-Based Urology Practice Join Dr. Neal Shore and his esteemed colleagues for this four-part webinar series focused on the implementation of IO, as well as other recently approved advanced bladder cancer therapies. This series was designed for all clinicians interested in bladder cancer […]
Neal Shore, MD, Article Featured in Notable Articles of 2020 by The New England Journal of Medicine. The New England Journal of Medicine editors have selected Dr. Shore’s article Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer to be featured in Notable Articles of 2020. This is a selection of articles that have been the most […]
Interview with Neal Shore, MD, FACS, about the approval of Relugolix for advanced prostate cancer and the significance of the treatment. Click here to read more.
Neal Shore, Steven A. Kaplan, Ronald Tutrone, Richard Levin, James Bailen, Alan Hay, Susan Kalota, Mohamed Bidair, Sheldon Freedman, Kenneth Goldberg, Frederick Snoy & Jonathan I. Epstein Click here to read more.
Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al. Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon […]
Neal D. Shore, Alicia K. Morgans, Charles J. Ryan Click here to read more.
Dr. Neal Shore Featured In Grand Strand Magazine Click here to read the article.
- Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
- Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come